Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425622 | 1.00 | MEN1 (0.36) | MEN1KMT2ALMNASLC9A1ALDH1A1 | |
| SCHEMBL21586906 | 0.89 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1RECQL | |
| SCHEMBL20045677 | 0.89 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1RECQL | |
| SCHEMBL18154462 | 0.89 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1RECQL | |
| SCHEMBL20045678 | 0.89 | MEN1 (0.40) | MEN1KMT2ALMNAALDH1A1RECQL | |
| SCHEMBL18144147 | 0.86 | MEN1 (0.38) | MEN1KMT2ALMNASLC9A1ALDH1A1 | |
| SCHEMBL18144141 | 0.86 | MEN1 (0.38) | MEN1KMT2ALMNASLC9A1ALDH1A1 | |
| SCHEMBL18144144 | 0.86 | MEN1 (0.38) | MEN1KMT2ALMNASLC9A1ALDH1A1 | |
| SCHEMBL23465651 | 0.85 | HTT (0.37) | MEN1KMT2ALMNASLC9A1ALDH1A1 | |
| SCHEMBL18144064 | 0.82 | TPMT (0.38) | MEN1KMT2ALMNASLC9A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3971166-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND COMPOSITIONS, AND PROCESSES, RELATED THERETO | Corteva Agriscience LLC (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3964495-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND COMPOSITIONS, AND PROCESSES, RELATED THERETO | Dow AgroSciences LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20190166847-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190150452-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-20180098541-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | DOW AGROSCIENCES LLC (US) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098541-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | MEN1 912/4885KMT2A 2547/4885LMNA 3330/4885 |
| US-20190166847-A1 | MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | MEN1 915/4885KMT2A 2668/4885LMNA 3336/4885 |
| US-20190150452-A1 | MOLECULES HAVEING PESTICIDAL UTILIY AND INTERMEDIATES, COMPOSITIONS AND PROCESSES RELATED THERETO | ACHE, DDT, MLYCD | MEN1 912/4885KMT2A 2547/4885LMNA 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.